Immatics NV stock (NL0015255052): T. Rowe Price discloses 16.1% stake – what it means for investors

A fresh Schedule 13G/A filing shows T. Rowe Price now holding a 16.1% stake in Immatics NV, highlighting growing institutional interest in the Nasdaq-listed cancer immunotherapy specialist.

T. Rowe Price has reported a 16.1% beneficial stake in Immatics NV via a new Schedule 13G/A filing, adding a notable long-term institution to the shareholder base of the Nasdaq?listed cancer immunotherapy developer, according to StockTitan as of 05/15/2026.

The amended filing states that T. Rowe Price Investment Management now reports beneficial ownership of 21,652,162 Immatics shares, representing 16.1% of the company’s common stock, based on the share count referenced in the document, according to StockTitan as of 05/15/2026.

As of: 05/16/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Immatics N.V.
• Sector/industry: Biotechnology, oncology immunotherapies
• Headquarters/country: Tübingen, Germany
• Core markets: Cancer immunotherapies for the US and European markets
• Key revenue drivers: Collaboration payments and milestone revenues from partnered T cell therapies
• Home exchange/listing venue: Nasdaq (ticker: IMTX)
• Trading currency: US dollar (USD)

Immatics NV: core business model

Immatics NV is a clinical?stage biopharmaceutical company focused on developing T cell?redirecting immunotherapies for the treatment of cancer. The group uses its proprietary platforms to identify tumor?specific targets and engineer T cell products that can recognize and destroy cancer cells, according to the company’s description in its latest filings and corporate materials published in 2025.

The company’s operations are split between Germany and the United States, with research and development in Tübingen and a strong clinical and corporate presence in Houston, Texas, reflecting its strategic focus on the US oncology market, as outlined in its Form 20?F filed in 2025. Its programs span engineered T cell receptor (TCR) therapies and bispecific antibody?like molecules designed to redirect T cells to tumors.

Immatics typically advances its lead assets through early? and mid?stage clinical trials, while using partnerships with large pharmaceutical companies to help fund development and share commercialization responsibilities. These collaborations can involve upfront payments, research funding, and potential milestone and royalty streams, which play a crucial role in supporting a pipeline that is not yet at the commercial revenue stage.

Like many clinical?stage biotech firms, Immatics’ business model is highly dependent on continued access to capital markets and strategic partners. The company invests heavily in research and development, and it generally posts operating losses while its product candidates move through clinical testing, according to its full?year 2024 financial report published in early 2025. This dynamic makes the strength and stability of its shareholder base particularly important.

Main revenue and product drivers for Immatics NV

Immatics currently generates the bulk of its revenues from collaboration and license agreements rather than from product sales, as it has no approved therapies on the market yet, according to its annual report for the year ended December 31, 2024, published in 2025. These revenues can fluctuate significantly depending on the timing of milestone achievements and research funding recognition.

One of the key long?term value drivers for Immatics is its pipeline of adoptive cell therapies based on engineered T cell receptors (TCR?T). These product candidates are designed to recognize cancer?specific peptides presented on HLA molecules, potentially enabling targeted killing of tumor cells while sparing healthy tissue, as described in company presentations and scientific updates in 2024 and 2025. Progress in these clinical programs, including safety and efficacy data from ongoing trials, will be closely watched by investors.

In parallel, Immatics is advancing its “T cell engaging” biologics platform, which focuses on bispecific molecules that link T cells to tumor cells. These assets can offer an off?the?shelf approach compared with individualized cell therapies, an aspect the company highlights in its pipeline overview in investor materials published in 2025. For investors, this platform may represent an additional diversification of potential revenue sources beyond personalized therapies.

On the financial side, recent commentary suggests that Immatics has experienced some volatility in near?term revenues and expectations. A Spanish?language analysis noted that quarterly revenues of about €7.8 million came in roughly 14% below analyst estimates, reflecting the inherently lumpy nature of collaboration income, according to Simply Wall St as of 03/2026. At the same time, the same analysis pointed to consensus expectations for an annualized revenue growth rate of around 17% through 2026, compared with roughly 5.8% per year over the previous five years, based on estimates cited as of early 2026.

These projections underline how much of Immatics’ perceived value is anchored in anticipated future growth rather than current top?line levels. Success in advancing late?stage candidates, securing additional partnerships, or entering into licensing deals could materially influence the company’s revenue trajectory and help it transition from a predominantly research?funded model toward a more product?driven one over the coming years.

Institutional interest: T. Rowe Price and other holders

The recent disclosure by T. Rowe Price adds another layer to the Immatics investment story. In its Amendment No. 4 to Schedule 13G/A filed on May 15, 2026, T. Rowe Price Investment Management reported beneficial ownership of 21,652,162 Immatics shares, equivalent to a 16.1% stake in the company’s common stock, with 21,600,896 shares carrying sole voting power, according to StockTitan as of 05/15/2026.

Schedule 13G filings are typically associated with passive stakes, suggesting that T. Rowe Price is positioning Immatics as part of its broader biotech or healthcare portfolios rather than seeking an activist role. The magnitude of the stake nonetheless signals a significant level of conviction in the company’s long?term prospects. For a clinical?stage biotech without approved products, such backing from a well?known US asset manager may provide additional confidence to other market participants regarding funding resilience.

Other institutional holders have also been updating their positions. A separate Schedule 13G/A amendment indicated that RTW Investments reported shared beneficial ownership of 12,869,340 Immatics shares, representing about 9.6% of the class based on 134,071,432 shares outstanding as of December 31, 2025, according to StockTitan as of 02/2026. In addition, Vestal Point Capital disclosed ownership of 6,175,000 ordinary shares, equal to about 4.6% of the outstanding class, in another recent 13G/A filing, according to StockTitan as of 02/2026.

Together, these disclosures illustrate a concentrated institutional shareholder base, with several specialized healthcare and growth?oriented investors holding sizable stakes. For existing and prospective shareholders, this structure can have multiple implications. On the one hand, it may support liquidity and signal that industry specialists have conducted detailed due diligence. On the other hand, it could also mean that sentiment shifts within this relatively tight group of investors have an outsized impact on the stock’s medium?term trading pattern.

For US retail investors following the Nasdaq biotechnology segment, the growing involvement of institutions such as T. Rowe Price and RTW may be interpreted as a sign that Immatics has progressed beyond the earliest, most speculative phase of company development. It still remains a high?risk clinical?stage name, but one that has attracted attention from professional portfolio managers with a long?term focus on oncology innovation and potential breakthroughs in T cell?based therapies.

Conclusion

The latest Schedule 13G/A filing highlighting T. Rowe Price’s 16.1% stake in Immatics NV underscores the growing role of institutional investors in shaping the shareholder structure of this clinical?stage cancer immunotherapy company. Alongside sizeable positions held by RTW Investments and Vestal Point Capital, the disclosure points to a concentrated but engaged base of professional owners. For US?based investors watching the Nasdaq biotechnology space, Immatics offers exposure to T cell?based oncology innovation, but its future value remains closely tied to clinical trial outcomes, partnership dynamics, and the company’s ability to manage funding needs. As with many development?stage biotechs, potential upside is balanced by substantial scientific, regulatory, and financing risks that investors need to weigh carefully.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.